AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis

Phase 3

Completed

Conditions: Psychosis

First Posted Date: 2007-03-20

Last Posted Date: 2011-01-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 150

Registration Number: NCT00449397

Locations: 🇦🇺
Research Sites, Melbourne, Australia

A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2007-03-20

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 123

Registration Number: NCT00449527

Locations: 🇺🇸
Research Site, Tacoma, Washington, United States

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2007-03-20

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 134

Registration Number: NCT00449501

Locations: 🇺🇸
Research Site, Spokane, Washington, United States

Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients

Phase 3

Completed

Conditions: Mania
Bipolar Disorder

First Posted Date: 2007-03-19

Last Posted Date: 2010-12-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 150

Registration Number: NCT00448578

Locations: 🇨🇳
Research Site, Wu han, China
🇨🇳
Research Sites, Beijing, China

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Phase 2

Completed

Conditions: Obesity
Overweight

Interventions: Drug: pramlintide acetate

First Posted Date: 2007-03-08

Last Posted Date: 2015-06-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 184

Registration Number: NCT00444561

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients

Phase 4

Completed

Conditions: GERD

Interventions: Drug: esomeprazole (Nexium®)
Drug: Xolaam®

First Posted Date: 2007-03-07

Last Posted Date: 2012-12-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 3029

Registration Number: NCT00444275

Locations: 🇫🇷
Research Site, Rouen, France

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Phase 3

Completed

Conditions: Gastric Ulcer
Duodenal Ulcer

Interventions: Drug: Placebo
Drug: Esomeprazole 20 mg
Drug: Esomeprazole 40 mg

First Posted Date: 2007-03-01

Last Posted Date: 2012-07-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 2426

Registration Number: NCT00441727

Locations: 🇹🇭
Research Site, Chiang Mai, Thailand

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Tiotropium
Drug: Placebo Tiotropium
Drug: Aclidinium bromide
Drug: Placebo LAS34273

First Posted Date: 2007-02-15

Last Posted Date: 2016-11-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 115

Registration Number: NCT00435760

Locations: 🇬🇧
Respiratory Clinical Trials Ltd, London, United Kingdom

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil
Drug: Hydrochlorothiazide
Drug: Candesartan/HCT 32/25 mg

First Posted Date: 2007-02-14

Last Posted Date: 2010-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 2207

Registration Number: NCT00434967

Locations: 🇸🇰
Research Site, Sahy, Slovakia

Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: exenatide twice daily (BID)
Drug: premixed insulin aspart twice daily (BID)

First Posted Date: 2007-02-14

Last Posted Date: 2015-04-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 494

Registration Number: NCT00434954

Locations: 🇩🇪
Research Site, Wolfsburg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy